About: Responding to the Pandemic of Falsified Medicines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Responding to the Pandemic of Falsified Medicines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Responding to the Pandemic of Falsified Medicines
Creator	Attaran, Amir Kendall, Megan Newton, Paul Breman, Joel Clark, John Culzoni, M Fernandez, Facundo Herrington, James Nayyar, Gaurvika
topic	covid:57f687e997bc7338adaefa13542e1f9ae7ddd7e6#this
source	Medline; PMC
abstract	Over the past decade, the number of countries reporting falsified (fake, spurious/falsely labeled/counterfeit) medicines and the types and quantities of fraudulent drugs being distributed have increased greatly. The obstacles in combating falsified pharmaceuticals include 1) lack of consensus on definitions, 2) paucity of reliable and scalable technology to detect fakes before they reach patients, 3) poor global and national leadership and accountability systems for combating this scourge, and 4) deficient manufacturing and regulatory challenges, especially in China and India where fake products often originate. The major needs to improve the quality of the world's medicines fall into three main areas: 1) research to develop and compare accurate and affordable tools to identify high-quality drugs at all levels of distribution; 2) an international convention and national legislation to facilitate production and utilization of high-quality drugs and protect all countries from the criminal and the negligent who make, distribute, and sell life-threatening products; and 3) a highly qualified, well-supported international science and public health organization that will establish standards, drug-quality surveillance, and training programs like the U.S. Food and Drug Administration. Such leadership would give authoritative guidance for countries in cooperation with national medical regulatory agencies, pharmaceutical companies, and international agencies, all of which have an urgent interest and investment in ensuring that patients throughout the world have access to good quality medicines. The organization would also advocate strongly for including targets for achieving good quality medicines in the United Nations Millennium Development Goals and Sustainable Development Goals.
has issue date	2015-06-03(xsd:dateTime)
bibo:doi	10.4269/ajtmh.14-0393
bibo:pmid	25897060
has license	cc-by
sha1sum (hex)	57f687e997bc7338adaefa13542e1f9ae7ddd7e6
schema:url	https://doi.org/10.4269/ajtmh.14-0393
resource representing a document's title	Responding to the Pandemic of Falsified Medicines
has PubMed Central identifier	PMC4455086
has PubMed identifier	25897060
schema:publication	Am J Trop Med Hyg
resource representing a document's body	covid:57f687e997bc7338adaefa13542e1f9ae7ddd7e6#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/57f687e997bc7338adaefa13542e1f9ae7ddd7e6
is schema:about of	named entity 'drugs' named entity 'The organization' named entity 'detect' named entity 'production' named entity 'develop' named entity 'Such' named entity 'accountability' named entity 'areas' named entity 'training' named entity 'utilization' named entity 'convention' named entity 'Administration' named entity 'Pandemic' named entity 'PANDEMIC' named entity 'GOALS' named entity 'FALL' named entity 'PHARMACEUTICALS' named entity 'GREATLY' named entity 'U.S.' named entity 'GLOBAL' named entity 'LEGISLATION' named entity 'POOR' named entity 'DEFICIENT' named entity 'PATIENTS' named entity 'NUMBER OF' named entity 'INCLUDE' named entity 'INTEREST' named entity 'INTERNATIONAL' named entity 'SPURIOUS' named entity 'MEDICINES' named entity 'LACK' named entity 'SYSTEMS' named entity 'CHALLENGES' named entity 'HEALTH ORGANIZATION' named entity 'LABELED' named entity 'PAST' named entity 'COMPANIES' named entity 'DISTRIBUTION' named entity 'DECADE' named entity 'CHINA' named entity 'TYPES' named entity 'FOOD AND DRUG ADMINISTRATION' named entity 'WHERE' named entity 'COMPARE' named entity 'TRAINING PROGRAMS' named entity 'GOOD QUALITY' named entity 'HAVE' named entity 'RESEARCH' named entity '27S' named entity 'UTILIZATION' named entity 'MANUFACTURING' named entity 'FAKES' named entity 'CONSENSUS' named entity 'TARGETS' named entity 'INCREASED' named entity 'PHARMACEUTICAL' named entity 'TECHNOLOGY' named entity 'AGENCIES' named entity 'LEVELS' named entity 'TO DETECT' named entity 'AUTHORITATIVE' named entity 'MAJOR' named entity 'MAIN' named entity 'NATIONAL' named entity 'MAKE' named entity 'INVESTMENT' named entity 'LIFE' named entity 'ACCURATE' named entity 'MILLENNIUM DEVELOPMENT GOALS' named entity 'DISTRIBUTED' named entity 'LIKE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software